A startup says ultrasound can deliver gene therapy. Two top Duchenne researchers aren't convinced.

A small California startup called Sonothera says it can deliver a corrective gene into the muscle cells of boys with Duchenne muscular dystrophy. Its method uses focused sound waves instead of the engineered viruses most gene therapies rely on. The animal data behind that bet is so striking that two of the field's senior researchers publicly called it "hard to believe" and "too good to be true". There is no human data, no independent peer-reviewed replication, and a concrete set of signals that would have to land for the field to take Sonothera seriously.

Duchenne muscular dystrophy is a fatal genetic muscle-wasting illness, mostly in boys, and currently has no cure. The standard gene-therapy playbook, in plain terms, uses a modified virus to carry a corrective gene into the cells that need it. Two real bottlenecks have defined that playbook for years. The viruses most teams use, called adeno-associated viruses or AAVs, are tiny, and the full-length dystrophin gene is too large to fit inside one. AAVs also provoke immune reactions; some patients are already immune to the most common variants before they ever receive treatment.

Sonothera's answer is a platform it calls RIPPLE. The company pairs a non-viral payload carrying the full-length human dystrophin gene with focused ultrasound that briefly opens muscle cells so the payload can slip in. Because there is no virus, the size and immunity bottlenecks are, in principle, addressed in one move. The data Sonothera has shown so far is preclinical: a full-length human dystrophin expression result in non-human primates, the MDA 2026 preclinical readout in Duchenne mouse models, and additional platform data presented at ASGCT 2026 covering multi-tissue delivery across skeletal, heart, and diaphragm muscle.

This is the part where the field pushes back. Eric Olson told STAT+ the data is "hard to believe" given how cleanly it appears to work across tissues. Jeffrey Chamberlain said the animal results read as "too good to be true." Both are speaking to the data, not the business: they have spent careers trying to deliver full-length dystrophin to muscle and know exactly how hard the problem is.

The standard of proof the field actually moves on is not a conference abstract or a corporate press release. It is human trials, peer-reviewed publication of the preclinical data, and independent replication in another lab. None of those exist yet. Patient-advocacy coverage has framed RIPPLE as a potential answer to the full-length dystrophin delivery problem, which is the right aspiration, but the company is still preclinical, and the publicly disclosed efficacy and safety data all come from Sonothera or Sonothera-affiliated authors.

Sonothera closed an oversubscribed $125 million Series B in 2025, earmarked for clinical development of ultrasound-mediated non-viral genetic medicines. Capital is not validation, but it is a clock. Clinical development means a first-in-human trial announcement, which is the first signal that would force the field to weigh the mechanism against a real human readout.

Three things are worth watching. A clinical trial announcement, ideally with a disclosed indication, dose, and ultrasound protocol. Peer-reviewed publication of the preclinical data, which is the format the field uses to evaluate mechanism, biodistribution, and immune response on its own terms. Independent replication of the multi-tissue delivery claim in another lab, the only way to separate the platform from the operator.

Sonothera has the bet, the mechanism, and the capital to test it. The next signal that lands will tell the field how seriously to take the data.